[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100533320":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":10,"centralContacts":10,"locations":20,"responsibleParty":39,"collaborators":41,"id":44,"slug":45,"hasResults":46,"nctId":47,"briefTitle":48,"officialTitle":49,"acronym":50,"eligibilityCriteria":51,"healthyVolunteers":46,"sex":52,"minAge":10,"maxAge":10,"enrollmentInfo":53,"targetDuration":10,"studyType":56,"phases":10,"briefSummary":57,"conditions":58,"keywords":10,"overallStatus":23,"whyStopped":10,"lastUpdateSubmitDate":60,"lastUpdatePostDateStruct":61,"startDateStruct":64,"completionDateStruct":66,"leadSponsor":68,"locationsCount":69},{"fullName":5,"class":6},"Istituto Ortopedico Rizzoli","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Performed cryotherapy",null,"Patients who received cryoablation for desmoid tumor and no chemotherapy",[13],"Procedure: Cryoablation",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":10},"PROCEDURE","Cryoablation","Cryoablation, a technique used in interventional radiology, involves repeated cycles of freezing, leading to cell death. Recent studies showed that percutaneous image-guided cryoablation appears to be safe and effective for local control for patients with extra-abdominal desmoid tumors",[9],[21],{"facility":22,"status":23,"city":24,"state":10,"zip":25,"country":26,"countryCode":27,"cosmosGeoPoint":28,"geoPoint":33,"contacts":34},"Giancarlo Facchini","RECRUITING","Bologna","40136","Italy","IT",{"type":29,"coordinates":30},"Point",[31,32],11.33875,44.49381,{"lat":32,"lon":31},[35],{"name":22,"role":36,"phone":37,"phoneExt":10,"email":38},"CONTACT","3336500944","giancarlo.facchini@gmail.com",{"type":40,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR",[42],{"name":43,"class":6},"University of Sao Paulo","100533320","radiomics-compared-with-conventional-response-criteria-for-predicting-progression-of-desmoid-tumor-after-cryoablation-100533320",false,"NCT06224283","Radiomics Compared With Conventional Response Criteria for Predicting Progression of Desmoid Tumor After Cryoablation","Confronto Tra Radiomica e i Criteri Convenzionali di Risposta Nella Previsione Della Progressione Del Tumore Desmoide Dopo Crioablazione","Cryomics","Inclusion Criteria:\n\n* desmoid tumor treated at Rizzoli Orthopaedic Institute with cryoablation\n* baseline MRI\n* clinical and radiologic follow-up until disease progression or the start of a new line of treatment performed every 3 months, with a minimum of 6 months follow-up\n\nExclusion Criteria:\n\n\\- not meeting inclusion criteria","ALL",{"count":54,"type":55},21,"ESTIMATED","OBSERVATIONAL","Desmoid tumors (DT) are uncommon tumors that arise from musculoaponeurotic structures. Despite benign, they can cause pain and disability due to their tendency to be locally aggressive. Cryoablation, a technique used in interventional radiology, has gained popularity in recent years as a treatment option for sporadic DT. This involves repeated cycles of freezing, leading to cell death. Recent studies showed that percutaneous image-guided cryoablation appears to be safe and effective for local control for patients with extra-abdominal desmoid tumors.Although changes in the heterogeneity of tumors are commonly known, they are often ignored in response criteria that only evaluate tumor size in a single dimension, such as Response Evaluation Criteria in Solid Tumors (RECIST 1.1). Nevertheless, MRI can reveal early changes in tumor heterogeneity in responding tumors, resulting from a reduction in cellular area and an increase in fibro-necrotic content, before any dimensional changes occur. These changes in heterogeneity can be quantified using a radiomics approach. The aim of this study is to develop radiomics response criteria dedicated to the evaluation of DT treated with cryoablation as a first line treatment and to compare their performance with those of alternative radiologic response criteria for predicting progression according to RECIST 1.1.",[59],"Desmoid","2026-05-11",{"date":62,"type":63},"2026-05-12","ACTUAL",{"date":65,"type":63},"2024-02-20",{"date":67,"type":55},"2026-10-31",{"name":5,"class":6},1]